Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.

Chung-Han Lee,Renzo G. DiNatale,Diego Chowell,Chriag Krishna,Vladimir Makarov,Natalie Shapnik,Samuel Murray,Maria I. Carlo,Martin H. Voss,Darren R. Feldman,A. Ari Hakimi,Yusuke Adachi,Yukinori Minoshima,Junji Matsui,Yasuhiro Funahashi,Rodolfo F. Perini,Kenichi Nomoto,Robert J. Motzer,Timothy A. Chan

Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.

2020

Chung-Han Lee
Renzo G. DiNatale
Diego Chowell
Chriag Krishna
Vladimir Makarov
Natalie Shapnik
Samuel Murray
Maria I. Carlo
Martin H. Voss
Darren R. Feldman
A. Ari Hakimi
Yusuke Adachi
Yukinori Minoshima
Junji Matsui
Yasuhiro Funahashi
Rodolfo F. Perini
Kenichi Nomoto
Robert J. Motzer
Timothy A. Chan

733Background: A phase 1b/2 clinical trial indicated that len/pembro shows promise in the treatment of renal cell carcinoma (RCC) in both PD-1/PD-L1 immune checkpoint blockade (ICB)-naive and pretr...

Keywords:

Oncology
Pathology
Biomarker (medicine)
Lenvatinib
Internal medicine
Renal cell carcinoma
Pembrolizumab
Medicine
Immune checkpoint
genomic biomarkers
Clinical trial
in patient
Blockade

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations